Valuation: Outlook Therapeutics, Inc.

Market Cap 21Cr 18Cr 17Cr 16Cr 29Cr 1.95TCr 30Cr 200.77Cr 78Cr 963.55Cr 78Cr 76Cr 3.34TCr P/E 2026 *
-3.29x
P/E 2027 * -6.49x
Enterprise Value 21Cr 18Cr 17Cr 16Cr 29Cr 1.95TCr 30Cr 200.77Cr 78Cr 963.55Cr 78Cr 76Cr 3.34TCr EV / Sales 2026 *
172x
EV / Sales 2027 * 4.52x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+6.21%
1 week+8.23%
Current month+134.25%
1 month+131.08%
3 months+721.72%
6 months-6.04%
Current year+8.23%
1 week 1.53
Extreme 1.5302
1.87
1 month 0.68
Extreme 0.6752
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
02/06Buy

Director

29,000 0.0181%
28/05
Gms Ventures & Investments
BuyCompany 3,95,16,849 24.6751%
27/05Buy

Chairman

1,22,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+6.21%+8.23%+6.88%-94.86% 21Cr
-0.48%+7.20%-5.65%+1.02% 4.62TCr
+2.19%+11.71%+393.31%+580.42% 3.87TCr
+2.53%+13.93%+21.38%-12.81% 3.19TCr
+1.65%+3.61%+16.04%+55.62% 3.11TCr
-4.16%-2.58%+8.94%+25.31% 2.38TCr
-0.32%+12.96% - - 1.62TCr
+1.37%+14.53%+69.64%+130.07% 1.51TCr
+1.00%+10.30%+13.31%+20.31% 1.37TCr
+3.63%+9.53%+103.97%+98.73% 1.34TCr
Average +1.36%+9.05%+69.76%+89.31% 2.3TCr
Weighted average by Cap. +0.76%+8.71%+88.67%+130.68%

Financials

2026 *2027 *
Net sales 12L 10.52L 10L 9L 17.03L 11Cr 17.38L 1.17Cr 45.11L 5.59Cr 45.06L 44.08L 19Cr 4.57Cr 4.01Cr 3.7Cr 3.46Cr 6.49Cr 431.36Cr 6.62Cr 44Cr 17Cr 213.19Cr 17Cr 17Cr 739.24Cr
Net income -5.34Cr -4.69Cr -4.32Cr -4.04Cr -7.58Cr -504.07Cr -7.74Cr -52Cr -20Cr -249.12Cr -20Cr -20Cr -863.84Cr -3.55Cr -3.12Cr -2.87Cr -2.69Cr -5.04Cr -335.33Cr -5.15Cr -35Cr -13Cr -165.73Cr -13Cr -13Cr -574.67Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26/26/26 $1.710 +6.21% 1,14,91,945
25/26/25 $1.610 -4.17% 91,47,785
24/26/24 $1.680 -1.18% 86,76,520
23/26/23 $1.700 -7.10% 1,07,92,078
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.710USD
Average target price
5.500USD
Spread / Average Target
+221.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock